Articles

The third quarter of 2026 was defined less by new readouts than by regulatory follow-through. Data from ASCO GU and the ASCO Annual Meeting turned into FDA approvals in muscle-invasive bladder cancer and metastatic hormone-sensitive prostate cancer, and biomarker-selected strategies moved firmly…

█ For kidney cancer, ESMO 2026 has one of its most concentrated programmes in years. Nearly all of the practice-relevant renal data come on a single day, Sunday, October 25. The morning Proffered Paper session puts both phase 3 belzutifan readouts, a…

Moshe C. Ornstein1,#, Xiayan Ye2,3, Sumita Dutta2,3, Venkateshwari Varadharajan2,3, Wei Wei4, Marcelo Lamenza1, Monaben Patel5, C. Marcela Diaz-Montero5, J. Mark Brown2,3,6,#, and Abhishek A. Chakraborty5,6,#Ϯ ABSTRACT BACKGROUND: The diagnosis and treatment of metastatic renal cell carcinoma (mRCC) is challenging. Drug combinations targeting…

doi.org/10.52733/ASCO26Summary Thomas E. Hutson, DO, PharmD, FACP Editor-in-Chief, Kidney Cancer Journal A Summary Report for the Global Oncology Community Chicago, Illinois  |  May 29 – June 2, 2026  |  Kidney Cancer Journal, Volume 24…

Nitinkumar Moradiya University Of Sunderland, Harbour Exchange Square, E14 9GE, London, United Kingdom. ABSTRACT Background: Kidney cancer is an emerging public health concern in India, with rising incidence rates and a significant economic burden. While global research has identified common risk…